Faculty Bibliography

Scientists at Stanford University say they have developed a novel way to generate a powerful immune response targeted specifically against non-Hodgkins lymphoma, a cancer of the lymph system. The Stanford researchers start the multistep process by removing two kinds of tissue from a lymphoma patient. One tissue is a dendritic cell, which is important in stimulating immune reactions in humans. The cells are obtained from the blood. The second tissue is the lymphoma, which is removed by a biopsy and from which researchers isolate a protein from the surface of the cancerous cells. The protein is specific for each patient's cancer. Then the protein is incubated in a laboratory with the patient's dendritic cells, a process that takes six months. Finally, the processed tissue is given back to the patient in a series of injections

Scientists at Stanford University say they have developed a novel way to generate a powerful immune response targeted specifically against non-Hodgkins lymphoma, a cancer of the lymph system. The Stanford researchers start the multistep process by removing two kinds of tissue from a lymphoma patient. One tissue is a dendritic cell, which is important in stimulating immune reactions in humans. The cells are obtained from the blood. The second tissue is the lymphoma, which is removed by a biopsy and from which researchers isolate a protein from the surface of the cancerous cells. The protein is specific for each patient's cancer

The Stanford researchers start the multistep process by removing two kinds of tissue from a lymphoma patient. They remove dendritic cells, which are important in stimulating immune reactions in humans. They are obtained from the blood. The researchers also remove tissue from the lymphoma, and researchers isolate a protein from the surface of the cancerous cells. The protein is specific for each patient's cancer. In developing the lymphoma therapy, Dr. Levy's team adapted a technique developed by Dr. Ralph M. Steinman's group at Rockefeller University in New York. It allows scientists to grow an individual's dendritic cells in a laboratory. If additional experiments show benefit for the immunotherapy, then Dr. Levy is hoping to improve the laboratory techniques. The current method forces the researchers to wait months for the cells to grow to produce enough protein. As a possible alternative, the Stanford team is removing genes from the cancer cells and then trying to produce large amounts of the cancer-specific-protein by using a technique known as the polymerase chain reaction.

Scientists at Stamford University say they have developed a novel way to generate a powerful immune response targeted specifically against non-Hodgkins lymphoma, a cancer of the lymph system. The researchers reported on Dec 29, 1995 in the journal Nature Medicine that results among four patients were promising

Scientists at Stanford University say they have developed a novel way to generate a powerful immune response targeted specifically at non-Hodgkins lymphoma, a cancer of the lymph system. The Stanford researchers start the multistep process by removing two kinds of tissue from a lymphoma patient. One tissue is a dendritic cell, which is important in stimulating immune reactions in humans. The cells are obtained from the blood. The second tissue is the lymphoma, which is removed by a biopsy and from which researchers isolate a protein from the surface of the cancerous cells. The protein is specific for each patient's cancer. Then the protein is incubated in a laboratory with the patient's dendritic cells, a process that takes six months. Finally, the processed tissue is given back to the patient in a series of injections

Scientists at Stanford University say they have developed a novel way to generate a powerful immune response to attack non-Hodgkins lymphoma, a cancer of the lymph system. The Stanford researchers start the multistep process by removing two kinds of tissue from a lymphoma patient. One tissue is a dendritic cell, which is important in stimulating immune reactions in humans. The cells are obtained from the blood. The second tissue is the lymphoma, which is removed by a biopsy and from which researchers isolate a protein from the surface of the cancerous cells. The protein is specific for each patient's cancer